Lentivectors (LVs) have attracted considerable interest for their potential as a vaccine delivery vehicle. In this study, we evaluate in mice a dendritic cell (DC)-directed LV system encoding the Gag protein of human immunodeficiency virus (HIV) (LV-Gag) as a potential vaccine for inducing an anti-HIV immune response. The
R ecombinant adenovirus-based vectors (rAd), used either alone or as a booster immunization after priming with a DNA plasmid, are among the most potent viral vectors for inducing human immunodeficiency virus (HIV)-specific T-cell responses in animals and humans (1, 2) . However, a phase 2b trial that used recombinant adenovirus serotype 5 (rAd5) vectors as the HIV vaccine carrier failed to show efficacy (3) (4) (5) (6) . This trial result is consistent with a preclinical study in which a rAd5-based vaccine expressing a simian immunodeficiency virus (SIV) Gag antigen failed to lower setpoint viral loads after SIV challenge of rhesus monkeys (7) . A recent study by Barouch and coworkers has shown that a heterologous prime/boost vaccine regimen using a newly identified rAd26 vector could elicit a strong and high quality immune response in non-human primates (NHP), resulting in markedly reduced viral loads and decreased AIDS-related mortality (8) . This study highlights the importance of exploring viral vector-based vaccine modalities for development of an effective HIV vaccine.
Efficient antigen delivery to antigen-presenting cells (APCs) and their subsequent presentation to stimulate virus-specific T cells is vital for the success of a T-cell-based vaccine. Dendritic cells (DCs) are the most powerful APCs to initiate and maintain immune responses of T cells (9) (10) (11) and therefore become one of the major target cells for the HIV vaccine development (12, 13) . Immunization by adoptive transfer of autologous DCs loaded in vitro with inactivated HIV particles induced anti-virus immunity in animals (14-16) and humans (17, 18) . However, this is a labor-intensive, personalized medicine approach, which limits its prospect as a vaccine design to deal with the worldwide AIDS pandemic. A direct method is to target the delivery of HIV immunogens to DCs in vivo (19, 20) . Steinman and coworkers reported a strategy to conjugate HIV Gag p24 and p41 onto an antibody to DEC-205, a relatively DC-restricted surface protein, as a means to load antigens into DCs in vivo for generating an immune response (21, 22) . Although with coadministration of appropriate adjuvants, a strong Gag-specific CD4 ϩ T-cell response was elicited (21) , it remains a challenge for this antibody fusion vaccine to evoke CD8 ϩ cytotoxic T cells, which are essential for controlling HIV replication.
We have developed a DC-targeted, lentivector (LV)-based system for delivery of genetic vaccines in vivo (23) . LV is known to be an efficient vehicle for genetic modification of DCs in vitro (24) , and direct injection with LV enveloped with glycoproteins with broad tropism is able to induce CD8 ϩ T-cell responses (25) (26) (27) (28) (29) (30) . To fully harness the immuno-stimulatory potency of DCs and mitigate off-target effects, we synthesized a LV enveloped with a Sindbis virus-derived glycoprotein engineered to be specific to the DC-specific surface protein DC-SIGN [also known as CD209 (31, 32)] (23); DC-SIGN has also been explored by others as the target receptor of DCs for protein antigen delivery (20, 33) . In our prior studies, we used ovalbumin (OVA) as a model antigen and found that a single-round immunization with this vector could result in substantial antigen-specific T-cell and antibody response (23) . In the present study, we show that the significant HIV Gag-specific immune response can be elicited by this DC-directed LV used alone or with other modalities.
Results

Immune Responses Generated by Various Routes of Vaccine Admin-
istration. We constructed a Gag-encoding lentiviral backbone plasmid by insertion of Gag cDNA into FUW (34) downstream of a human ubiquitin C promoter, a vector designated FUWGag ( Fig. 1A) . LV encoding the Gag immunogen and pseudotyped with the DC-directed envelope SVGmu was generated in 293T cells by transient transfection with appropriate combinations of various plasmids (see Materials and Methods) and is designated LV-Gag. We first tested a range of vector doses [1.25 ϫ 10 6 Ϸ10 ϫ 10 6 transduction units (TU)] for immunization of naive mice through footpad injection and found that a dose of 5 ϫ 10 6 TU generated the highest percentage of Gag-specific CD8 ϩ T cells 2 weeks after vaccination. We then assessed the immunogenic response to this vector dose via different administration routes. Naive mice were immunized with a single injection by the s.c. (s.c.), footpad (f.p.), intramuscular (i.m.), i.p. (i.p.), or intradermal (i.d., at the base of tail) route. Gag-specific T-cell responses were monitored by tetramer analysis and intracellular cytokine staining (ICCS). The f.p. and i.d. injections resulted in the strongest Gag-tetramer ϩ CD8 T-cell responses (Ϸ3%, Fig. 1B , left) 2 weeks postimmunization, consistent with these being the best routes to target skin DCs. The i.p. injection gave the lowest responses. When splenocytes harvested from vaccinated animals were restimulated in vitro with the Gagdominant peptide (AMQMLKETI), a similar trend for the pattern of IFN (IFN)-␥ producing CD8 ϩ T cells was observed ( Fig. 1B, right) .
HIV Gag-specific serum IgG and IgM could be detected 2 weeks postimmunization with the LV-Gag. The highest IgG titers were obtained from the f.p., i.d., and s.c. routes (Fig. 1C , left). Interestingly, the IgM titer showed a reverse trend, in which f.p. and i.d. injections yielded lower IgM production ( Fig. 1C , right). This suggests that immunization through these two injection routes yields a significant CD4 ϩ T-cell response, resulting in efficient isotype switching to convert IgM into IgG. Because of the superior response, the f.p. injection route was chosen for the subsequent prime/boost and other functional studies.
Enhanced Gag-Specific Immunity by Prime/Boost Regimens. To further characterize the efficacy of the LV-Gag immunization, four cohorts of mice were injected with PBS, empty LV (lacking the Gag transgene), bone marrow-derived DCs (BMDCs) loaded with the HIV-1 Gag dominant peptide and matured with lipopolysaccharide (LPS), or LV-Gag. Two weeks postinjection, we assessed IFN-␥-secreting CD8 ϩ T cells in freshly harvested splenocytes restimulated in vitro with the Gag peptide for all of the comparison groups. We observed that the LV-Gagimmunized mice displayed a significant fraction of CD8 ϩ T cells secreting IFN-␥, with a statistically significant difference (P Ͻ 0.01) when compared to the three comparison groups ( Fig. 2A ). The fact that the empty vector was not different from the PBS control suggests that the Gag-specific CD8 ϩ T cells elicited by LV-Gag results from the delivery of the vector-encoded transgene, rather than being elicited by Gag protein that might be carried within the vector particles. In addition, no significant level of epitope-specific responses was elicited by adoptive transfer of in vitro-loaded DCs, indicating that DC-directed delivery of Gag antigen by the LV in vivo is a much more potent vaccination method.
We next explored the utility of the LV-Gag vector in prime/ boost settings. Three groups of mice received either one dose of LV-Gag vector, a dose of LV-Gag vector prime followed by a homologous LV-Gag vector boost, or a DNA prime followed by a LV-Gag vector boost. Two weeks after the final injection, tetramer-positive and IFN-␥-producing CD8 ϩ T cells were quantified by flow cytometry (Fig. 2B ). Both assays showed an enhanced anti-Gag CD8 ϩ T cells response in the prime/boost animals compared to the single dose LV-Gag immunization group. Splenocytes from the different groups of animals were also cocultured with Gag peptide and then examined for IFN-␥ production by an ELISPOT assay ( Fig. 2C ). Obvious enhancement of IFN-␥ secretion was seen in the prime/boost groups, with 4-to 5-fold greater responses than for the single dose LV-Gag mice. We further measured the titers of HIV Gag-specific IgG and IgM antibodies in the sera from these animals and found that sera from LV-Gag/LV-Gag mice and DNA/LV-Gag mice showed higher responses to Gag protein than the single dose LV-Gag mice ( Fig. 2D ). Collectively, our data demonstrate that the DC-directed LV is an effective booster of responses initiated by either DNA or LV itself, enhancing CD8 ϩ T-cell as well as antibody responses.
Comparison of T-Cell Responses Elicited by Lentivector and Adenovec-
tor. We conducted experiments to compare DC-directed LV with the extensively studied rAd5 for their ability to induce the Gag-specific immune responses. Several groups of naive mice were immunized with a DNA prime/LV-Gag boost, LV-Gag prime/LV-Gag boost, or DNA prime/rAd5-Gag boost. Following the last immunization, comparable frequencies of IFN-␥producing and Gag-specific CD8 ϩ T cells were detected in splenocytes of the prime/boost vaccine groups (Fig. 3A) . Presumably due to the high rAd5 vaccine dose (10 10 VP) used in this study, we found that a single rAd5-Gag immunization was about as good as the prime/boost regimens.
Kinetic analysis of the early responses to single immunization showed that the magnitude of Gag-specific CD8 ϩ T-cell immunity with LV-Gag immunization declined after week 2 to approximately 1% IFN-␥-producing CD8 ϩ T cells by 4 weeks postvaccination ( Fig. 3B ). In contrast, the primary response to the rAd5-Gag vaccine reached a higher level at week 2, and active T cells were continuously expanded through week 4 (Fig. 3B ).
The memory phenotype of the Gag-specific CD8 ϩ T cells elicited by different regimens was studied by scoring the memory differentiation markers CD44 and CD62L. After gating on Gag-tetramer ϩ CD8 ϩ T cells among splenocytes from LV-Gagvaccinated mice, approximately 30% of them exhibited the central memory phenotype of CD44 hi CD62L ϩ , which was higher than the approximately 12% obtained from mice immunized with the rAd5-Gag vector (Fig. 3C ). The LV-Gag immunized cells also displayed a discrete very high CD62L population lacking in the rAd5-Gag immunized mice. This result suggests that the DC-targeted LV is more potent than rAd5 for induction of high quality memory T cells.
Multifunctional CD4 ؉ and CD8 ؉ T-Cell Responses Elicited by Lentivector. We examined the capacity of individual HIV-specific T cells to produce multiple cytokines, a parameter which was shown to correlate with a cell's ability to protect against infection in certain models (35) . We selected the LV-Gag/LV-Gag, DNA/ LV-Gag, and DNA/rAd5-Gag immunization regimens for the study because they were able to generate sufficiently high levels of responses to allow a reliable multifunctionality analysis. Splenocytes harvested from vaccinated animals were restimulated with a pool of 123 overlapping peptides covering the entire Gag protein. Intracellular cytokine levels were measured by multiparameter flow cytometry to assess the ability of single cells to produce various combinations of IFN-␥, interleukin (IL)-2 and tumor necrosis factor (TNF)-␣. As shown in Fig. 4A , although the DNA/rAd5-Gag elicited CD4 ϩ T cells that were single-positive for IFN-␥, IL-2, or TNF-␣, and double-positive for IFN-␥ and TNF-␣, there was no detectable level of these cells that were IFN-␥ ϩ IL-2 ϩ , IL-2 ϩ TNF-␣ ϩ , or IFN-␥ ϩ IL-2 ϩ TNF-␣ ϩ . In contrast, both the LV-Gag/LV-Gag and DNA/LV-Gag regimens generated substantial percentages of CD4 ϩ T cells that were IFN-␥ ϩ TNF-␣ ϩ , IFN-␥ ϩ /IL-2 ϩ , and IL-2 ϩ TNF-␣ ϩ . Especially, the DNA/LV-Gag group induced a high frequency of CD4 ϩ T cells secreting three cytokines simultaneously (6.4% of the responding cells). The distribution of Gag-specific CD8 ϩ T cells by various regimens showed the same pattern (Fig. 4A) . Compared with the DNA/rAd5-Gag immunization, a substantially greater proportion of the LV-Gag/LV-Gag-or DNA/LV-Gag-elicited CD8 ϩ T cells were able to secrete multiple cytokines, with approximately 3% of responding cells from the DNA/LV-Gag vaccine producing three cytokines. Interestingly, we found that CD4 ϩ T cells were more multipotent than CD8 ϩ T cells. Examining the IL-2-secreting CD4 ϩ T cells, we see that although the overall frequency of such cells was highest following DNA/rAd5-Gag immunization, only a slight portion of them secreted more than one cytokine (i.e., 2.8% of them are IL- 2 ϩ TNF-␣ ϩ ) (Fig. 4B ). On the contrary, at least half of the IL-2-secreting CD4 ϩ T cells from both DNA/LV-Gag and LV-Gag/LV-Gag vaccination were multicytokine producers, and a notable portion of them were able to generate three cytokines. Thus, both the CD4 ϩ and CD8 ϩ T cells induced by immunization involving DC-directed LV were more polyfunctional than those generated by the DNA/rAd5-Gag vaccine.
Breadth of T-Cell Responses Induced by Various Immunization Regimens.
To assess the breadth of the induced T-cell responses, we generated a peptide matrix as shown in Fig. 5A (36) . A library of peptides covering the entire HIV-1 Gag protein was divided into 23 pools named P1-P23, with each peptide present in two independent pools. The splenocytes of mice immunized with LV-Gag/LV-Gag, DNA/LV-Gag, and DNA/rAd5-Gag were stimulated by one of the peptide pools, and then assayed by IFN-␥ ELISPOT. In contrast to the T cells from DNA/rAd5-Gag immunized mice, those from LV-Gag/LV-Gag mice responded to many peptides. Taking an ELISPOT cut-off at 80 SFC (spot forming cells)/0.1 million cells, mice immunized with LV-Gag/ LV-Gag responded to eight peptide pools (P4, P5, P6, P9, P10, P15, P17, and P18) ( Fig. 5 B and C) , while the DNA/LV-Gag and DNA/rAd5-Gag mice only vigorously responded to three pools (P4, P5, and P17) ( Fig. 5 B and C) . We were able to verify the response of LV-Gag/LV-Gag T cells to 11 individual peptides derived from these responding eight peptide pools (Fig. S1 ). However, when the DNA/rAd5-Gag did respond to a peptide pool, its response was higher than that of the mice receiving LV-Gag. There were 15 different peptide pools identified as nonreactive (refers to the ELISPOT reading Ͻ20 SFC/0.1 million cells) to cells from the DNA/rAd5-Gag immunized mice. However, none of the pools were found to be nonreactive for either the LV-Gag/LV-Gag or DNA/LV-Gag induced T cells (Fig. 5B ). We also conducted an ICCS analysis of the LV-Gag/ LV-Gag splenocytes stimulated by two representative peptide pools (P6 and P10) and found that the ratio of Gag-specific CD8 vs. CD4 T-cell responses for both pools was approximately 3:1 (Fig. S2) . The above results indicate that the Gag-specific T cells generated by LV-Gag-involved vaccination regimens (LV-Gag/ LV-Gag and DNA/LV-Gag) can recognize a broader range of epitopes as compared to the T-cell response induced by the DNA/rAd5-Gag strategy. The DNA/rAd5-Gag-immunized mice gave a high total response but one much more focused on immune-dominant determinants. Number of highly reactive peptide pools versus number of nonreactive peptide pools for each group of mice was summarized as shown in (B). The threshold for defining a nonreactive peptide pool was based on the ELISPOT readout comparable with the control PBS group. A peptide pool was defined as highly reactive when its stimulated response was 5 times higher than that of the control PBS reading and could be obviously detected by an ICCS assay.
Discussion
We have previously shown that one can build a replicationdeficient LV that targets a gene of interest directly to DCs in an animal to induce antigen-specific immune responses (23) . In this study, we examine a special case, the production of T cells and antibodies against the Gag protein of HIV. This is of particular interest because attempts to make a vaccine against HIV have failed thus far and a new and more effective vector system is needed (5, 6) . When this vector was used to deliver Gag immunogen (LV-Gag), a significant quantity of Gag-specific CD8 ϩ T cells could be detected upon a single injection. We performed a direct comparison of the LV-Gag with rAd5-Gag with the respect to magnitude, kinetics and the memory nature of the induced cellular immune response. A single round immunization of rAd5-Gag induced a stronger immunity than LV-Gag at the chosen doses. The time-course measurement showed that LV-Gag resembled a usual immune response of expansion and contraction, but rAd5-Gag provoked a persistent response. This persistent immunization of rAd-Gag vector might stem from the continuously active transcription of adenovirus vector at the site of injection (37) and could present a challenge for generating high quality memory T cells (2, 5) . This unusually prolonged response of rAd5-Gag can compromise its utilities for repeated immunization [such a protocol was used by Merck's STEP trial (3, 4) ] because the sustained APCs and neutralizing antibodies may inhibit responses from further homologous vaccination. As compared with the rAd5-Gag vector, LV-Gag induced a greater percentage of Gag-specific memory T cells that were of the central memor y phenotype (T CM : CD44 high CD62L ϩ ).
Heterologous prime/boost strategies have been well-studied for AIDS vaccines, especially with a rAd5-based vector (38, 39) . Unlike the adenoviral vector, the DC-directed LV is less likely to be restricted by the preexisting immunity, thus we tested its application for both homologous and heterologous vaccination regimens. We demonstrated that the DNA/LV-Gag as well as LV-Gag/LV-Gag displayed a remarkable enhancement of vaccine efficacy for generation of HIV-specific T-cell and antibody responses. Although generation of a robust CD8 ϩ T-cell response is one requirement for a HIV vaccine, the magnitude itself is not necessarily predictive of a superior control of HIV infection in many individuals (40) . Therefore, we further investigated the functional potency and breadth of LV-Gag-induced T-cell responses. The CD8 ϩ T cells from the DNA/rAd5-Gag regimen were primarily IFN-␥ ϩ , TNF-␣ ϩ , and IFN-␥ ϩ TNF-␣ ϩ cells, with few of them secreting IL-2. The ability of CD8 ϩ T cells to generate IL-2 could be significant because it should allow them to survive and expand (41) . Moreover, the central memory CD8 ϩ T cells which home to lymphoid organs are thought to produce IL-2, while the effector counterparts are restricted to peripheral tissues and primarily secrete IFN-␥ (42) . Promisingly, our data indicate that there is a significant portion of HIVspecific CD8 ϩ T cells generated by either DNA/LV-Gag or LV-Gag/LV-Gag that are IL-2 producers. Notably, approximately 3% of the cytokine-producing DNA/LV-Gag-induced CD8 ϩ T cells produced three cytokines.
CD4 ϩ T cells, especially the polyfunctional ones, are of great importance to vaccine responses (43) . Consistent with the results of Sun et al. (42) , we observed that IFN-␥ and TNF-␣ production dominated the CD4 ϩ T-cell population induced by DNA/rAd5-Gag immunization. The functional profiles of Gag-specific CD4 ϩ T cells elicited by DNA/LV-Gag and LV-Gag/LV-Gag were different from that of DNA/rAd5-Gag. This may not be too surprising, considering that LV-Gag and rAd5-Gag target different cell populations through distinct cellular receptors and are likely to mediate different forms of antigen presentations. IL-2 ϩ TNF-␣ ϩ cells represented the highest portion of CD4 ϩ T cells in the DNA/LV-Gag and LV-Gag/LV-Gag groups, with IFN-␥ ϩ IL-2 ϩ , IFN-␥ ϩ TNF-␣ ϩ , and IFN-␥ ϩ IL-2 ϩ TNF-␣ ϩ Gagspecific CD4 ϩ T cells at detectable levels. Several studies on the SIV-macaque model revealed that prolonged survival of infected monkeys was associated with the preservation of SIVspecific CD4 ϩ T cells producing IFN-␥, IL-2, and TNF-␣ (8, 40, 44) . The frequency of CD4 ϩ T cells producing three cytokines simultaneously was also positively related to protection against Leishmania major infection (35) . Furthermore, CD4 ϩ T cells were reported to be indispensable for secondary CD8 ϩ T-cell expansion, and the depletion of them during the priming phase led to deficient development of functional CD8 ϩ T-cell memory (41, 45) . The role of CD4 ϩ T cells is particularly important in a prime/boost vaccination, because CD4 ϩ T cells help establishment of CD8 ϩ T-cell functionality and expansion in the boost phase of immunization (46) . Balanced CD8 ϩ and CD4 ϩ T-cell responses are thought to be highly desirable for vaccine effectiveness, and were suggested by Liu et al. to explain an efficient priming by rAd26 vectors (8) . This cytokine profile study reveals that DNA/LV-Gag is very effective regimen to produce both multifunctional CD8 ϩ and CD4 ϩ HIV-specific T cells in mice.
We further assessed the breadth of antigen recognition displayed by vector-induced T cells. Our experiments showed that there were three peptide pools that elicited the most vigorous responses for all three groups of mice given a prime/boost regimen. Although the magnitude of DNA/rAd5-Gag response to the three dominant peptide pools was the highest, there was a greater diversification of immunogen recognition by the DNA/ LV-Gag and LV-Gag/LV-Gag regimens. We speculate that through the DC targeting, the vaccination involved with LV-Gag might load and present antigens more efficiently in the DCs, allowing the generation of broader responses (38) . Our polyfunctional study also supports the notion that this wider epitope response might be the result of a better CD4 ϩ T-cell response.
In summary, we report an effort to evaluate an anti-HIV vaccination involving a LV directed to DCs. We found that both the DNA/LV-Gag and LV-Gag/LV-Gag vaccination regimens elicited multifunctional CD4 ϩ and CD8 ϩ Gag-specific T cells, and the DNA/LV-Gag method generated the highest frequencies of CD4 ϩ and CD8 ϩ cells secreting three cytokines simultaneously. Homologous or heterologous immunization using LV-Gag-induced T cells recognizing a wide range of Gag epitopes. This study in mice demonstrates that this DC-targeted LV is a promising vector system and should warrant further investigations in NHP to continue the evaluation of its potential for future human HIV/AIDS vaccine development.
Materials and Methods
Mice and Vaccination Procedure. Six-to eight-week-old female BALB/c mice were purchased from Charles River Laboratories. All animal procedures were performed in accordance with the guidelines set by the National Institutes of Health and the University of Southern California on the Care and Use of Animals. The details of immunization protocols are described in the SI Text.
Plasmid Construction and Vector Production. The plasmid encoding the DCtargeted envelope SVGmu was constructed as described in ref. 23 . FUWGag was constructed by insertion of the cDNA of a HIV-1 subtype B Gag into the lentiviral backbone plasmid FUW (34) downstream of the human ubiquitin C promoter. The production of LV-Gag and rAd5-Gag vectors is described in the SI Text. Staining (ICCS) . The details of tetramer staining, staining for phenotypic analysis, ICCS, and multiparameter ICCS are described in the SI Text.
Tetramer Staining and Intracellular Cytokine
Antibody ELISA and IFN-␥ ELISPOT Assays. Antibody responses were assessed by ELISA using the method described before (see SI Text) (47) . ELISPOT assays were performed for IFN-␥ using a kit from Millipore according to the manufacturer's instruction (see SI Text ).
Statistical Analysis. The significance of the difference between groups was evaluated by analysis of variance followed by a one-tailed Student t test.
IFN-␥ ELISPOT Assay. ELISPOT assays were performed for IFN-␥ using a kit from Millipore according to the manufacturer's instruction. Briefly, anti-mouse IFN-␥ antibody (10 g/mL in PBS) was used as the capture antibody and plated 100 L/well on 96-well MultiScreen-IP plates overnight at 4°C. The plate was decanted and blocked with RPMI medium containing 10% FBS at 37°C for 2 h. Splenocytes from mice were plated at 1 ϫ 10 5 cells/well in 150 L complete medium in company with stimulus, which are HIV-1 Gag single peptide (2 g/mL) or pools of peptides (at a final concentration of 3 g/mL for each peptide) for this assay. After 18 h incubation at 37°C, cells were lysed by water and plates were detected by 0.5 g/mL biotinylated anti-IFN-␥ antibody (BD Biosciences) for 2 h at room temperature. Plates were further washed and incubated with the 1,000-fold-diluted streptavidin-alkaline phosphate conjugate for 45 min at room temperature. After a final extensive wash, spots were identified by addition of BCIP/NBTplus substrate, and the number of IFN-␥ producing cells was quantified by an ELISPOT reader. Fig. S1 . Confirmation of the response of T cells from LV-Gag/LV-Gag mice to individual peptides derived from the peptide pool study. The amino acid sequences of these peptides are: 1, eeeqnkskkkaqqaa; 2, nkskkkaqqaaadtg; 3, kkaqqaaadtghsnq; 4, sqnypivqniqgqmv, 5, amqmlketineeaae; 6, lketineeaaewdrv; 7, drvhpvhagpiapgq; 8, pvhagpiapgqmrep; 9, stlqeqigwmtnnpp; 10, pvgeiykrwiilgln; and 11, iykrwiilglnkivr. 
